H
Hans-Georg Kopp
Researcher at Bosch
Publications - 22
Citations - 2513
Hans-Georg Kopp is an academic researcher from Bosch. The author has contributed to research in topics: Progression-free survival & Lung cancer. The author has an hindex of 8, co-authored 22 publications receiving 1176 citations. Previous affiliations of Hans-Georg Kopp include Robert Bosch Hospital.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
Journal ArticleDOI
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard Jack West,Michael McCleod,Maen A. Hussein,Alessandro Morabito,Achim Rittmeyer,Henry Jacob Conter,Hans-Georg Kopp,Davey B. Daniel,Steven L. McCune,Tarek Mekhail,Alona Zer,Niels Reinmuth,Ahad Sadiq,Alan Sandler,W. Lin,Tania Ochi Lohmann,V. Archer,Lijia Wang,Marcin Kowanetz,Federico Cappuzzo +19 more
TL;DR: IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer and the intention-to-treat wild-type population.
Journal ArticleDOI
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Steven Francis Powell,Delvys Rodriguez-Abreu,Corey J. Langer,Ali Tafreshi,Luis Paz-Ares,Hans-Georg Kopp,Jerónimo Rodríguez-Cid,Dariusz M. Kowalski,Ying Cheng,Takayasu Kurata,Mark M. Awad,Jinaxin Lin,Bin Zhao,M. Catherine Pietanza,Bilal Piperdi,Marina Chiara Garassino +15 more
TL;DR: In this paper, the authors evaluated outcomes in patients with advanced NSCLC to determine whether baseline brain metastases influenced the efficacy of first-line pembrolizumab plus chemotherapy versus chemotherapy alone.
Journal ArticleDOI
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Grünwald,Annika Karch,Markus K. Schuler,Patrick Schöffski,Hans-Georg Kopp,Sebastian Bauer,Bernd Kasper,Lars H. Lindner,Jens-Marcus Chemnitz,Martina Crysandt,Alexander Stein,Björn Steffen,Stephan Richter,Gerlinde Egerer,Philipp Ivanyi,Silke Zimmermann,Xiaofei Liu,Annegret Kunitz +17 more
TL;DR: Pazopanib was noninferior to doxorubicin, rendering pazobanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older and may be used to counsel patients and tailor therapy to individual needs.
Journal ArticleDOI
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Julien Mazieres,Dariusz M. Kowalski,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Konstantin Laktionov,Barbara Hermes,Irfan Cicin,Jerónimo Rodríguez-Cid,Jonathan Wilson,Terufumi Kato,Rodryg Ramlau,Silvia Novello,Sreekanth Reddy,Hans-Georg Kopp,Bilal Piperdi,Xiaodong Li,Thomas Burke,Luis Paz-Ares +19 more
TL;DR: The results support use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC and maintained or improved HRQoL measurements relative to baseline and improved HRZoL versus chemotherapy alone at weeks 9 and 18.